Financial Incentive for Smoking Cessation in Pregnancy (FISCP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02606227|
Recruitment Status : Recruiting
First Posted : November 17, 2015
Last Update Posted : January 12, 2018
Maternal smoking during pregnancy (MSDP) increases the risk of adverse pregnancy and birth outcomes and may have long-lasting effects in the offspring.Financial incentives may increase smoking abstinence rate in pregnancy and therefore reduce MSDP related negative health effects. This is a randomized open label study comparing financial incentives for smoking abstinence with no financial incentives for smoking abstinence.Research objectives
- To test the efficacy of financial incentives on smoking abstinence rate among pregnant smokers;
- To explore the heterogeneity of efficacy according to individual characteristics: socioeconomic status, social background, smoking characteristics, personality traits, time and risk preferences to determine profiles of women which could benefit best from this kind of intervention;
- To provide a cost-benefit analysis based on the cost of newborn and children disease due to maternal smoking during pregnancy.
|Condition or disease||Intervention/treatment||Phase|
|Pregnancy Smoking||Behavioral: Financial incentive Other: No financial incentive||Not Applicable|
Multicenter, national study. Participants are pregnant smokers of at least 18 years old, smoking at least 5 manufactured or 3 rolled-on-their-own cigarettes per day. They will be randomly assigned according to a 1:1 ratio to receive either a financial incentive (20€/visit) to attend the 5 study visits (control group) or receive this show-up incentive plus an incentive for being abstinent at visit(s) on a progressive manner (treatment group). The incentives will be delivered as vouchers. Two hundred and forty pregnant smokers will be randomized into the control and treatment groups, respectively. The study will be run in several maternity wards across France all of whom routinely treat pregnant smokers.
- Financial incentives rewarding progressive abstinence from smoking will increase abstinence rate more than lack of financial incentives.
- Forward looking and time consistent women will be more likely to stop smoking.
- If the clinical efficacy and cost effectiveness are demonstrated, financial incentives can be introduced as a standard intervention in helping pregnant smokers quit.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||480 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Financial Incentive for Smoking Cessation in Pregnancy|
|Study Start Date :||April 2016|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2019|
Experimental: Experimental group:financial incentives
Vouchers for show up + Vouchers at increasing amount to reward tobacco abstinence
Behavioral: Financial incentive
Control group:no financial intervention
Vouchers for show up only, no financial incentive for rewarding tobacco abstinence
Other: No financial incentive
No financial intervention
- Continuous smoking abstinence since target quit date until last visit before delivery. [ Time Frame: Last 6 months of pregnancy ]Self-report of no smoking confirmed by expired air carbon monoxyde ≤8 ppm at all visits.
- Birth weight [ Time Frame: Newborns' weight at birth ]
- 7-day point prevalence abstinence [ Time Frame: Last 6 months of pregnancy ]Self-report of no smoking confirmed by expired air carbon monoxyde ≤8 ppm.
- Time to relapse to smoking [ Time Frame: Between quit date and last visit before delivery, a maximum time frame of 6 months. ]Time in days between predefined quit date and first cigarette smoked after quit date as ascertained at the presential visits and relapse confirmed by expired air CO higher than 8 ppm and self-report of smoking.
- Craving for tobacco [ Time Frame: Last 6 months of pregnancy ]12 item French Tobacco Craving questionnaire (FTCQ12)
- Tobacco withdrawal symptoms [ Time Frame: Last 6 months of pregnancy ]Updated Minnesota Nicotine Withdrawal Scale (NMWS)
- Urinary anabasine (ng/mL) [ Time Frame: At baseline and at a randomly chosen visit before delivery ]Biological markers of tobacco use (anabasine, anatabine) or nicotine uptake (cotinine)
- Urinary anatabine (ng/mL) [ Time Frame: At baseline and at a randomly chosen visit before delivery ]Biological markers of tobacco use (anabasine, anatabine) or nicotine uptake
- Urinary cotinine (ng/mL) [ Time Frame: At baseline and at a randomly chosen visit before delivery ]Biological markers of tobacco use (anabasine, anatabine) or nicotine uptake
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02606227
|Contact: BERLIN Ivan, MD||33(0)email@example.com|
|Groupe Hospitalier Pitié-Salpétrière||Recruiting|
|Paris, France, 75013|
|Contact: BERLIN Ivan|
|Principal Investigator:||BERLIN Ivan||Assistance Publique - Hôpitaux de Paris|